Autolus sets IPO pricing terms
London-based Autolus, a biopharmaceutical company focused on developing and commercializing T-cell therapies, is expecting to price its IPO of 7.8 million shares at between $15 and $17 per share. The stock will trade on the NASDAQ under the ticker symbol "AUTL." Goldman Sachs and Jefferies LLC are serving as lead underwriters. Autolus’ backers include Arix Bioscience plc, Cormorant Asset Management, Nextech Invest, Syncona and Woodford Investment Management.
11 June 2018•3 mins read
